Structure of the house dust mite allergen Der f 2: implications for function and molecular basis of IgE cross-reactivity

The X-ray structure of the group 2 major allergen from Dermatophagoides farinae (Der f 2) was determined to 1.83 A resolution. The overall Der f 2 structure comprises a single domain of immunoglobulin fold with two anti-parallel beta-sheets. A large hydrophobic cavity is formed in the interior of Der f 2. Structural comparisons to distantly related proteins suggest a role in lipid binding. Immunoglobulin E (IgE) cross-reactivity between group 2 house dust mite major allergens can be explained by conserved surface areas representing IgE binding epitopes.     

Introduction to current and future protein therapeutics: a protein engineering perspective

Protein therapeutics and its enabling sister discipline, protein engineering, have emerged since the early 1980s. The first protein therapeutics were recombinant versions of natural proteins. Proteins purposefully modified to increase their clinical potential soon followed with enhancements derived from protein or glycoengineering, Fc fusion or conjugation to polyethylene glycol. Antibody-based drugs subsequently arose as the largest and fastest growing class of protein therapeutics. The rationale for developing better protein therapeutics with enhanced efficacy, greater safety, reduced immunogenicity or improved delivery comes from the convergence of clinical, scientific, technological and commercial drivers that have identified unmet needs and provided strategies to address them. Future protein drugs seem likely to be more extensively engineered to improve their performance, e.g., antibodies and Fc fusion proteins with enhanced effector functions or extended half-life. Two old concepts for improving antibodies, namely antibody-drug conjugates and bispecific antibodies, have advanced to the cusp of clinical success. As for newer protein therapeutic platform technologies, several engineered protein scaffolds are in early clinical development and offer differences and some potential advantages over antibodies.     

Conjugation of Multiple Copies of Polyethylene Glycol to Hemoglobin Facilitated Through Thiolation: Influence on Hemoglobin Structure and Function

PEGylation induced changes in molecular volume and solution properties of HbA have been implicated as potential modulators of its vasoconstrictive activity. However, our recent studies with PEGylated Hbs carrying two PEG chains/Hb, have demonstrated that the modulation of the vasoconstrictive activity of Hb is not a direct correlate of the molecular volume and solution properties of the PEGylated Hb and implicated a role for the surface charge and/or the pattern of surface decoration of Hb with PEG. HbA has now been modified by thiolation mediated maleimide chemistry based PEGylation that does not alter its surface charge and conjugates multiple copies of PEG5K chains. This protocol has been optimized to generate a PEGylated Hb, (SP-PEG5K)₆-Hb, that carries ~six PEG5K chains/Hb – HexaPEGylated Hb. PEGylation increased the O₂ affinity of Hb and desensitized the molecule for the influence of ionic strength, pH, and allosteric effectors, presumably a consequence of the hydrated PEG-shell generated around the protein. The total PEG mass in (SP-PEG5K)₆-Hb, its molecular volume, O₂ affinity and solution properties are similar to that of another PEGylated Hb, (SP-PEG20K)₂-Hb, that carries two PEG20K chains/Hb. However, (SP-PEG5K)₆-Hb exhibited significantly reduced vasoconstriction mediated response than (SP-PEG20K)₂-Hb. These results demonstrate that the enhanced molecular size and solution properties achieved through the conjugation of multiple copies of small PEG chains to Hb is more effective in decreasing its vasoconstrictive activity than that achieved through the conjugation of a comparable PEG mass using a small number of large PEG chains.     

两种联合切口手术治疗眶-上颌-颧骨复合体骨折的对比研究

目的：对比研究冠状-睑下缘-口内联合切口手术与冠状切口联合口腔前庭沟切口手术治疗眶-上颌-颧骨复合体骨折的治疗效果。方法：选取2006年10月-2010年12月眶-上颌-颧骨复合体骨折患者136例,69例患者行冠状-睑下缘-口内联合切口手术,67例行冠状切口联合口腔前庭沟切口手术,分别命名为A组和B组,比较两组患者治疗效果,治疗效果用甲级、乙级和丙级表示。结果：A组治疗效果甲级、乙级、丙级分别为65．2％、30．4％、4．4％,B组治疗效果甲级、乙级、丙级分别为46．3％、29．8％、23．9％,A组治疗效果优于B组;A组术后并发症少于B组。结论：冠状-睑下缘-口内联合切口手术比冠状切口联合口腔前庭沟切口手术更好地治疗眶-上颌-颧骨复合体骨折,治疗效果好,并发症少,能更好地实现颧骨复位。     

牛磺胆酸钠在大鼠急性胰腺炎模型中的半数致死量（LD50）研究

目的：通过使用不同浓度的牛磺胆酸钠（Tc）建立急性胰腺炎（AP）模型,观察相应的死亡率,进而计算其半数致死量。方法：使用不同浓度的TC（0％（wt／v1）、1％、2％、3％、4％、5％、9％）观察AP造模72小时后各组的死亡率。同时分析TC浓度与组织病理评分、血清淀粉酶和外周血细胞变化的相美性。结果：TC的卓数致死量为3．409％。并且,TC的浓度与组织病理评分、血清淀粉酶和外周血细胞变化密切相关。结论：TC所致AP造模的最佳剂量为3．409％。     

低氧脑水肿大鼠脑组织VEGF和AQPs基因及蛋白表达的变化

目的：探讨低氧脑水肿时血管内皮细胞生长因子（VEGF）、水通道蛋白（AQP1和AQP4）基因和蛋白表达变化,为阐明急性低氧对脑组织的损伤及低氧脑水肿的发病机制提供实验依据。方法：Wistar大鼠随机分为4个组：常氧对照组（Control）、低氧暴露4 000 m组（4 000 m）、低氧暴露6 000 m组（6 000 m）和低氧暴露8 000 m组（8 000 m）,低氧组于低压舱中模拟相应海拔高度持续暴露8 h建立低氧脑水肿模型。用干-湿重法测定脑组织水含量,常规光镜观察脑组织形态学的改变;用RT-PCR法和免疫组化法检测低氧脑水肿时大鼠脑组织VEGF、AQP1和AQP4mRNA和蛋白表达的变化。结果：①干-湿重法测定表明,低氧（≥6 000 m）暴露后,大鼠脑组织水含量明显增加（P〈0.01）。②常规光镜检测结果表明,低氧暴露4 000 m时大鼠脑神经细胞、血管内皮细胞和星形胶质细胞足突轻度肿胀,组织中出现漏出液;低氧暴露6 000 m时脑血管内皮细胞和星形胶质细胞足突肿胀加重,血管与组织间隙扩大,组织中漏出液增多;低氧暴露8 000m时脑血管内皮细胞和星形胶质细胞足突重度肿胀,血管与组织间隙进一步扩大,组织中漏出液明显增多。③低氧脑水肿时,VEGF、AQP1、AQP4mRNA表达水平增高,AQP1在内皮细胞异常表达,内皮细胞VEGF和AQP1、星形胶质细胞足突AQP4蛋白质表达水平增高。结论：低氧脑水肿时,VEGF、AQP1和AQP4表达和分布的变化可能是引起血脑屏障损伤、导致低氧脑水肿的发病机制之一。     

锰作用下PC12细胞的氧化应激机制研究

目的：以鼠嗜铬神经瘤细胞（PC12）为模型,筛选锰对神经细胞增殖抑制作用的时间及剂量,观察锰作用下PC12细胞的氧化应激反应与细胞形态学、生化指标改变和丝裂原活化蛋白激酶pp38（p38MAPKs）的活化表达。方法：用200,400,600,800μmol/LMnCl2的培养液,分别作用对数生长期PC12细胞1,2,3,4d后,用MTT筛选锰的细胞毒性剂量;测定200-600μmol/L MnCl2作用4d后,PC12细胞还原型谷胱甘肽和丙二醛含量;透射电镜观察细胞形态学变化;琼脂糖凝胶电泳检测MnCl2对PC12细胞基因组DNA的影响。western-blot法检测p-p38。结果：MTT实验显示200~800μmol/LMnCl2作用1,2,3,4d对PC12有显著的抑制作用,呈剂量和时间依赖趋势,600μmol/LMnCl2作用4d对PC12的抑制率可达50%以上。200-600μmol/LMnCl2作用于细胞4d后,随着浓度的升高,还原型GSH逐渐降低,MDA的含量逐渐升高;600μmol/LMnCl2作用4d电镜可见细胞凋亡,同样条件下细胞DNA碎片化。Western-blot实验显示600μmol/LMnCl2作用1,2,3,4dp-p38逐渐升高,3d时较对照组增加6.6倍（n=3,p〈0.05）,200,400,600μmol/L MnCl2作用4d时,磷酸化蛋白38（p-p38）也逐渐升高,400μmol/L MnCl2作用4d时较对照组升高了4.7倍（n=3,p〈0.05）。结论：PC12细胞在锰作用下发生氧化应激反应,上调p-p38,诱导细胞凋亡,细胞增殖抑制。     

Roles of carboxyl groups in the transmembrane insertion of peptides

We have used pHLIP® [pH (low) insertion peptide] to study the roles of carboxyl groups in transmembrane (TM) peptide insertion. pHLIP binds to the surface of a lipid bilayer as a disordered peptide at neutral pH; when the pH is lowered, it inserts across the membrane to form a TM helix. Peptide insertion is reversed when the pH is raised above the characteristic pK_a (6.0). A key event that facilitates membrane insertion is the protonation of aspartic acid (Asp) and/or glutamic acid (Glu) residues, since their negatively charged side chains hinder membrane insertion at neutral pH. In order to gain mechanistic understanding, we studied the membrane insertion and exit of a series of pHLIP variants where the four Asp residues were sequentially mutated to nonacidic residues, including histidine (His). Our results show that the presence of His residues does not prevent the pH-dependent peptide membrane insertion at ∼ pH 4 driven by the protonation of carboxyl groups at the inserting end of the peptide. A further pH drop leads to the protonation of His residues in the TM part of the peptide, which induces peptide exit from the bilayer. We also find that the number of ionizable residues that undergo a change in protonation during membrane insertion correlates with the pH-dependent insertion into the lipid bilayer and exit from the lipid bilayer, and that cooperativity increases with their number. We expect that our understanding will be used to improve the targeting of acidic diseased tissue by pHLIP.